Novo Nordisk A/S and Eli Lilly & Co. shares fell after President Donald Trump said the price of the blockbuster diabetes drug ...

A troubled Indiana contract manufacturing plant recently acquired by Novo Nordisk is considered to not be in compliance with ...

According to Benzinga Pro, Novo Nordisk AS's peer group average for short interest as a percentage of float is 4.29%, which means the company has less short interest than most of its peers. Did you ...

At the STAT Summit in Boston yesterday, Kyle and Nicole Muldoon shared the story of how their son, Baby KJ — once facing ...

ClearBridge Global Value Improvers Strategy generated positive absolute returns, but trailed its MSCI World Value Index ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.